Women diagnosed with polyendocrine metabolic ovarian syndrome (PMOS) will soon benefit from annual NHS checks, according to new guidance from health regulator NICE. This change aims to address the under-diagnosis and inconsistent management of PMOS, which affects approximately one in eight women in the UK. The condition, previously known as polycystic ovary syndrome, can lead to serious health issues, including infertility and increased risks of diabetes and heart disease.
The guidelines recommend that annual reviews not only focus on the primary symptoms but also assess long-term health risks. This proactive approach is crucial, as many women, like Sharon Manship, have faced lengthy delays in diagnosis, often waiting over a decade for proper care. The hope is that these new checks will facilitate earlier diagnosis and more effective management of PMOS, ultimately improving the quality of life for those affected.
Moreover, the guidelines highlight the importance of considering ethnicity in assessments, as PMOS is believed to be more prevalent among women of Black, Asian, and mixed ethnic backgrounds. Mental health impacts are also acknowledged, with recommendations for support in managing anxiety and depression, which are common among those living with PMOS.
As NICE opens the draft guidelines for consultation until August 2026, the final recommendations are expected to be published in December 2026. This initiative marks a significant step towards enhancing awareness and care for women with PMOS, ensuring they receive the attention and treatment they deserve from healthcare professionals.
Source: BBC News
